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Abstract
Background: Airway hyper-responsiveness (AHR) is a key feature of asthma and a causal relationship between airway
inflammation and AHR has been identified. The aim of the current study was to clarify the effect of proinflammatory
cytokines and asthma medication on primary human airway smooth muscle (ASM) inositol phosphate (IPx) signalling and
define the regulatory loci involved.
Methods: Primary Human ASM cells were isolated from explants of trachealis muscle from individuals with no history
of respiratory disease. The effect of cytokine or asthma medication on histamine or bradykinin induced IPx signalling was
assessed by [3H] inositol incorporation. Quantitative Real Time PCR was used to measure mRNA levels of receptors
and downstream signalling components. Transcriptional mechanisms were explored using a combination of 5'Rapid
Amplification of cDNA Ends (5'RACE) and promoter-reporter techniques.
Results: Treatment of Human ASM cells with IL-13, IFNγ or salmeterol for 24 hours lead to a modest augmentation of
histamine induced IPx responses (144.3 +/- 9.3, 126.4 +/- 7.5 and 117.7 +/- 5.2%, p < 0.05). Similarly, TNFα, IFNγ or
salmeterol treatment augmented bradykinin induced IPx responses (127.4 +/- 8.3, 128.0 +/- 8.4 and 111.7 +/- 5.0%, P <
0.05). No treatment significantly influenced sodium fluoride induced IPx responses suggesting regulation occurs at the
receptor locus. Analyses of mRNA expression of components of the IPx pathway i.e. H1 Histamine Receptor (HRH1),
B2 Bradykinin Receptor (BDKRB2), Gαq/11 and PLC-β1 identified that a significant induction of receptor mRNA (>2
fold) was a feature of these responses explaining the cytokine and spasmogen specificity. The HRH1 and BDKRB2
promoter regions were mapped in ASM and promoter-reporter analyses identified that salmeterol can induce HRH1 (>2
fold) and BDKRB2 (2–5 fold) transcription. The effect of cytokines on HRH1 and BDKRB2 promoter-reporter
expression suggested a more complex regulation of mRNA expression involving additional loci to the core promoter.
Conclusion: Our results indicate that the spasmogen specific receptor locus may be a key site of regulation determining
the magnitude of spasmogen mediated ASM IPx responses during airway inflammation or following asthma medication.
These data provide further insight into the molecular basis of AHR and extend our understanding of potentially
detrimental effects associated with existing therapies used in the treatment of asthma.
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Background
Asthma is characterised by airway inflammation, reversi-
ble airway narrowing and airway hyper-responsiveness
(AHR) caused by stimuli that normally elicit limited or no
response. Excessive smooth muscle contractility has long
been recognized as a feature of asthma, emphasised by the
fact that drugs designed to prevent or reverse bronchocon-
striction are still the most effective drug classes available.
Spasmogens such as acetylcholine, bradykinin and hista-
mine induce airway smooth muscle (ASM) contraction
via inositol phosphate/calcium signalling mechanisms
and thereby regulate the tone and calibre of the airways
[1,2].
There is strong evidence for a causal relationship between
airway inflammation and altered airway function includ-
ing hyperreactivity to contractile agents and hyporeactiv-
ity to relaxant agents in asthma [3]. It has been shown that
several cytokines are elevated in the lung during inflam-
mation in asthma including; interleukin (IL)1β, Tumour
Necrosis Factor (TNF)α [4] and IL13 [5]. Administration
of the recombinant cytokine to mouse airways e.g. IL-13,
has been shown to mimic several of the features of asthma
including AHR [6]. Similarly, viral infection has been
associated with asthma exacerbation and increased AHR
and this is thought to be mediated at least in part by ele-
vated interferon (IFN)γ expression in the airways [7].
Recently, it has also been shown that elevated CD4+IFNγ+
and CD8+IFNγ + cells are a feature of asthmatic airways
and that CD8+IFNγ + cell numbers correlated with AHR
[8]. A direct interaction between cytokines and Human
ASM has been described involving alterations in the
capacity of airway smooth muscle in culture to respond to
relaxation and contractile agents [9,10]. Proinflammatory
cytokines including; IL1β, TNFα and IL-13 have been
shown to augment bradykinin induced Ca2+ release in
human ASM cells in culture [11-13]. Similarly, studies
have been completed in order to determine the effect of
cytokines on other agonist mediated responses (e.g. hista-
mine or acetylcholine) including inositol phosphate (IPx)
signalling, however, data have been conflicting [14,15].
Recently, a mechanism involving a role for the CD38/
cyclic adenosine diphosphate pathway in regulating cal-
cium homeostasis has been proposed at least in part to
explain the effects of cytokines on agonist induced Ca2+
signalling [16]. IL-13 treatment of Human ASM in culture
was shown to increase expression of CD38 mRNA which
was accompanied by an increase in ADP-ribosyl cyclase
activity and net intracellular Ca2+ responses to bradykinin
and histamine [17].
Asthma maintenance medications including long acting
β2-adrenoceptor agonists and inhaled corticosteroids
have been shown to suppress AHR in the short term in vivo
[18,19] and are the mainstay therapy for asthma. While
clinically effective in many patients, concerns have been
raised regarding potential adverse effects associated with
chronic use of β2-adrenoceptor agonists [20-22] An
increase in bronchial hyper-responsiveness in response to
histamine has been observed following chronic use of the
short acting β2-adrenoceptor agonist, salbutamol in
asthma and COPD patients [23]. We have recently identi-
fied a potentially deleterious effect of prolonged exposure
of Human ASM cells in culture to short acting β2 adreno-
ceptor agonists [24]. Prolonged treatment (24 hours) of
Human ASM with salbutamol or isoprenaline augmented
histamine mediated IPx production potentially providing
a cellular mechanism explaining the clinical observations
[24]. Recently, the outcomes of the Salmeterol Multicen-
tre Asthma Research Trial (SMART) have been published
which involved the assessment of 26,355 subjects [22].
This study indicated that prolonged use of the long acting
β2-adrenoceptor agonist, salmeterol was associated with
respiratory related deaths [22] suggesting that the adverse
effects inferred for short acting β2-adrenoceptor agonists
may also be of clinical importance for long acting β2-
adrenoceptor agonist therapy.
Contractile agents including histamine, bradykinin and
acetylcholine bind to G-protein coupled receptors
(GPCR) on the surface of ASM which leads to the dissoci-
ation of Gαq from βγ subunits. Both Gαq and βγ subunits
are capable of binding and activating phospholipase C
(PLC)β1 which catalyses the generation of inositol 1,4,5-
triphosphate (IP3) and diacylglycerol (DAG) from phos-
phatidyl 4,5-biphospate (IP2). These second messengers
stimulate Ca2+ release from intracellular stores and pro-
tein kinase C (PKC) activity, resulting in the activation of
contractile and growth machinery in ASM [25].
There is accumulating evidence suggesting that the G-Pro-
tein Coupled Receptor (GPCR) may be a key regulatory
locus i.e. the level of receptor expression provides specifi-
city to the augmentation of signalling responses in airway
smooth muscle cells [9]. This has been demonstrated for
multiple GPCRs including; Cysteinyl leukotriene receptor
1 [26], β2 adrenoceptor [27], H1 histamine receptor [28]
and B2 bradykinin receptor [29] where increases in mRNA
levels are accompanied by augmented spasmogen
responses following cytokines or drug treatment.
In the current study we aimed to comprehensively define
the effect of key pro-inflammatory cytokines, IL1β, TNFα,
IL-13, IFNγ together with dexamethasone and salmeterol
on Human ASM IPx signalling pathways using a combina-
tion of cell signalling, gene expression and promoter anal-
yses.Respiratory Research 2007, 8:68 http://respiratory-research.com/content/8/1/68
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Methods
Reagents
All chemicals were analytical grade or higher. Plasticware
was from Costar (High Wycombe, UK). All chemicals and
reagents were purchased from Sigma-Aldrich (Poole, UK)
unless otherwise stated. The [3H]-myo-inositol was pur-
chased from Perkin Elmer (Bucks, UK). Inositol free
DMEM was made to order by Invitrogen (Paisley, UK).
Cell Culture
Human airway smooth muscle cells (ASM) were isolated
from explants of trachealis muscle obtained from individ-
uals with no history of respiratory disease as described
[24,30]. Briefly, a section of trachealis muscle was isolated
by dissection just above the carina and washed in Dul-
becco's Modified Eagle's Medium (DMEM) supplemented
with penicillin (200 U/ml), streptomycin (200 µg/l) and
amphotericin B (0.5 µg/l). Explants (0.2 × 0.2 cm) were
placed in 6 well plates and allowed to adhere. Cells were
allowed to grow with fresh complete medium (10% foetal
calf serum and 2 mM glutamine) added regularly, follow-
ing 7–10 days growth cells approached confluency. As
cells reached confluency, explants were removed and the
cells were harvested using 5 mg/ml trypsin/2 mg/ml
EDTA. Primary ASM cells exhibited >95% cell staining for
α-actin. Airway smooth muscle cells were maintained in
complete medium and passaged using trypsin/EDTA. Eth-
ical approval for the use of primary cells was obtained
from the local ethics committee. Airway smooth muscle
cells from four individuals were used.
Quantification of [3H]-inositol phosphates
[3H]-inositol phosphate formation in primary human
ASM cells was quantified essentially as described [24,30].
Briefly, cells were plated in 24 wells at a density of 0.5 ×
105 cells/well. Cells were allowed to grow for 2–3 days
until ~80% confluent, then medium was replaced with
300 µl of inositol free DMEM, supplemented with 2 mM
glutamine and containing [3H]-myo-inositol at a concen-
tration of 8.1 MBq/ml. Cells were then incubated for 24
hours followed by the addition of IL-1β, TNFα, IFNγ (10
ng/ml), IL-13 (50 ng/ml) (PeproTech EC Ltd, London,
UK), dexamethasone (1 µM) or salmeterol (1 µM) and
incubated for a further 24 hours. The medium was then
removed and cells were washed three times with 1 ml
Hanks/20 mM HEPES and 300 µl Hanks/20 mM HEPES
containing 20 mM LiCl was added. Cells were incubated
for 30 min at 37°C, then agonists were added in a volume
of 10 µl (100 µM Histamine, 0.1 µM Bradykinin or 10
mM Sodium Fluoride). Cells were incubated for a further
30 min and then the reaction was stopped by removing
the medium and addition of 1 ml ice cold 50% methanol/
60 mM HCl. Samples were stored at -20°C for at least 24
h. An 800 µl aliquot of each sample was neutralised using
~4.6 ml 5.5 mM Tris-HCl/11 mM NaOH. Total [3H]-inosi-
tol phosphates were separated from unincorporated [3H]-
inositol using anion-exchange chromatography on
Dowex-Cl columns and measured using scintillation
counting [24,30].
Quantification of HRH1, BDKRB2, GNA11 and PLCB1 
gene expression
Human ASM cells were transferred to 100 mm Petri dishes
at a density of 105 cells/ml. Cells were allowed to grow for
2–3 days until ~80% confluent. Complete medium was
replaced with serum free medium and the cells were
grown for a further 24 hours followed by the addition of
cytokines or drugs (as described above). Isolation of cells
for RNA extraction (at 4 and 24 hours post cytokine or
drug addition) involved removing medium, a phosphate
buffered saline (PBS) wash and collection in 1 ml PBS
using a cell scraper. Cells were collected by centrifugation
(300 × g 5 min), supernatant discarded and cell pellets
resuspended in 50 µl PBS. 450 µl RNAlater was added to
each sample followed by mixing and storage at -80°C.
Total RNA was extracted from samples using the RNAeasy
kit (Qiagen) as directed by the manufacturer. cDNA was
generated from 1 µg RNA template using random hexam-
ers and the Superscript kit (Invitrogen, Paisley, UK) as
directed by the manufacturer. TaqMan assays specific for
the Histamine H1 Receptor (HRH1), Bradykinin B2
Receptor (BDKRB2), Gαq/11 protein (GNA11) and
phosholipase C-β1 (PLCB1) transcripts were designed
using Primer Express Software (Applied Biosystems, War-
rington, UK). See Table 1. Real Time PCR (Applied Biosys-
tems) was carried out as directed by the manufacturer in a
reaction volume of 20 µl containing ~100 ng of cDNA,
300 nM of each Primer, 200 nM Probe (Eurogentec Ltd,
Southampton, UK) and 10 µl universal mastermix
(Applied Biosystems). Differences in the quantity of
cDNA template were normalised using a VIC labelled 18s
ribosomal RNA endogenous control (Applied Biosys-
tems). PCR was performed using the ABI-7700 and data
collected using Sequence Detection Software (Applied
Biosystems). Data was analysed as directed by the manu-
facturer and Ct values were normalised using the 18s
ribosomal RNA signal. Relative differences in gene expres-
sion were calculated using the 2dCt value as continuous
variable (Sequence Detection System Compendium 7700
Version 4.0, Applied Biosystems).
5'Rapid Amplification of BDKRB2 cDNA ends
5'RACE was performed in order to identify the putative
promoter regions of the BDKRB2 gene in Human ASM.
Total RNA was extracted from Human ASM cells derived
from two different donors. Total RNA extractions were
performed using the RNeasy Mini Kit (Qiagen, Crawley,
UK) as described above. 5'RACE was performed using the
GeneRacer Kit (Invitrogen) according to the manufac-
turer's protocol. 2.5 µg of total RNA was used as template.Respiratory Research 2007, 8:68 http://respiratory-research.com/content/8/1/68
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The mRNA was reverse-transcribed with SuperScript II RT
(Invitrogen) and the GeneRacer OligodT primer (50 µM)
to generate RACE ready cDNA. A nested PCR approach
was used to identify the 5' structure of the BDKRB2 gene;
PCR1 (GeneRacer 5'Primer/BDKRB2 primer 1 specific for
the open reading frame of the BDKRB2 gene). Reaction
conditions included; 1 µl RACE ready cDNA template,
0.025 U/µl Platinum Taq DNA Polymerase High Fidelity
(Invitrogen), 0.6 µM of each primer, 200 µM dNTPs, 2
mM Magnesium Sulphate and a staged PCR cycling
approach; 94°C for 5 min, 94°C for 1 min 30 sec/72°C
for 3 min × 5, 94°C for 1 min 30 sec/70°C for 1 min 30
sec/72°C for 3 min × 5, 94°C for 1 min 30 sec/68°C for 1
min 30 sec/72°C for 3 min × 20 and a final extension of
72°C for 10 min. The second stage PCR (PCR 2) utilised
nested primers (GeneRacer 5' Nested Primer/BDKRB2
primer 2 specific for the open reading frame of the
BDKRB2 gene). Reaction conditions were as described for
PCR 1 except 1 µl cDNA (from PCR1) was used as tem-
plate and PCR cycling involved; 94°C for 5 min, 94°C for
1 min 30 sec/68°C for 1 min 30 sec/72°C for 3 min × 25
and a final extension of 72°C for 10 min. 5'RACE prod-
ucts generated in PCR 2 were cloned into the pCR-4-
TOPO vector using the TOPO TA Cloning Kit for Sequenc-
ing as directed by the manufacturer (Invitrogen). LB agar
plates and LB broths (100 µg/mL ampicillin) were used to
select and grow single colonies of positive clones. Plasmid
DNA was purified using the FastPlasmid Mini Kit (Eppen-
dorf, Cambridge, UK) and the presence of inserts was con-
firmed by restriction analysis with EcoRI (Promega,
Southampton, UK). Positive clones showing an insert
after restriction digest were sequenced using M13 primers
(Invitrogen), ABI BigDye Terminator v3.1 Cycle Sequenc-
ing Kit and ABI Prism 310 DNA sequencer (Applied Bio-
systems). Sequences were analysed and the 5' structure of
the BDKRB2 gene identified using Chromas v2.0 ([31])
and BLAST (NCBI).
Table 1: Primers and probes
REAL TIME PCR
GENE 5'PRIMER 3'PRIMER PROBE (5'FAM/
3'TAMRA)
LOCATION
HRH1 TCTCGGTGGCGGACTTGA CATGAGCAGGTAGAGGATGTT
CAT
CGTGGGTGCCGTCGT ORF
BDKRB2 GATCAGCACCTTCCTGGATACG GATGATGCGCTCGTCCTGG CATCGCCTCGGCATCC
TCTCCA
ORF
GNA11 TCAGCGAATACGACCAAGTCC AGGGCTTTGCTCTCCTCCA TGGAGTCGGACAACGA
GAACCGG
Exon 5/6 boundry
PLCB1 CTGCCTGCTGTCTTTGTCTACATA
G
TCGGATTGGGTTTGATAAAGCT TGAAAGACTATGTGCC
AGACACA 
TATGCAGATG
Exon 22/23 boundary
5'RACE PRIMER 1 (PCR 1) PRIMER 2 (PCR 2)
BDKRB2 CACGAACAGCACCCAGAGGAAGG CCAGCCCAGCCACTCCACTTG
PLASMID CONSTRUCTION  
5'PRIMER
3'PRIMER LOCATION IN 
CONTIG
CONSTRUCT
HRH1-1 CTGACTCGAGCCTCCTCTCCCTG
TGAGCTT
CTGAAAGCTTGCCGGCTCCG
GGGAAAGTT
51,750 – 52,761 HRH1 1 kb
HRH1-2 CTGACTCGAGGAAAGTGTGGAC
GCAGCCATT
CTGAAAGCTTGCCGGCTCCG
GGGAAAGTT
50,782 – 52,761 HRH1 2 kb
HRH1-3 CTGACTCGAGGTTCAATCATAGC
TCACTGCAG
CTGAAAGCTTGCCGGCTCCG
GGGAAAGTT
49,768 – 52,761 HRH1 3 kb
HRH1-4 CTGACTCGAGTCCACAGCTTGTT
GCACAGC
CTGAAAGCTTGCCGGCTCCG
GGGAAAGTT
48,718 – 52,761 HRH1 4 kb
BDKRB2-1 CTGACTCGAGCCCAGGCCACCC
ATAAACTG
CTGAAAGCTTCAAGCGGCATG
GGCACTTCA
101,405 – 102,439 BDKRB2 1 kb
BDKRB2-2 CTGACTCGAGGGGCGGATGTGT
GGGTAGAT
CTGAAAGCTTCAAGCGGCATG
GGCACTTCA
100,436 – 102,439 BDKRB2 2 kb
BDKRB2-3 CTGACTCGAGCCTCCTATGTGCC
GGGTGAT
CTGAAAGCTTCAAGCGGCATG
GGCACTTCA
99,416 – 102,439 BDKRB2 3 kb
BDKRB2-4 CTGACTCGAGATGTTGGCCAGGC
TGATCTC
CTGAAAGCTTCAAGCGGCATG
GGCACTTCA
98,414 – 102,439 BDKRB2 4 kb
*HRH1 reference contig = AC083855, BDKRB2 reference contig = AL355102.5. Bold denotes HindIII and XhoI restriction sites.Respiratory Research 2007, 8:68 http://respiratory-research.com/content/8/1/68
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Luciferase Reporter Plasmid Construction
PCR primers were designed to generate 1, 2, 3 and 4 kb
amplicons encompassing the predicted BDKRB2 tran-
scription start sites (TSS) in HASM but not crossing the
ExonI/IntronI interface (see Table 1). The most 3' TSS was
at position 95,741,003 NCBI Build 35 (102,403 bp within
AL355102.5)). A repeat polymorphism [GGTGGGGAC]n
exists in this region therefore DNA fragments were gener-
ated to include the common n = 2 repeat observed in the
Caucasian population [32]. Primers were designed to
engineer a 5' HindIII and a 3' XhoI site into the DNA frag-
ments to facilitate cloning into the pGL4-Luc2 vector
(Promega). The BDKRB2 4 kb PCR included; 1 µl genomic
DNA template (Caucasian), 0.025 U/µl Platinum Taq
DNA Polymerase High Fidelity, 0.2 µM of each primer,
200 µM dNTPs, 2 mM Magnesium Sulphate and cycling
parameters; 94°C for 2 min, 94°C for 30 sec/62°C 30 sec/
68°C for 4 min × 30 and a final extension of 68°C for 7
min. The PCR product was cloned into the pCR-4-TOPO
vector and sequenced (as described above). The
sequenced pCR-4 vector containing the BDKRB2 4 kb
fragment was used as PCR template for the generation of
the BDKRB2 1, 2 and 3 kb fragments as described above.
The 1, 2, 3 and 4 kb BDKRB2 fragments were excised from
the pCR-4 vectors using HindIII/XhoI and cloned into
pGL4-Luc2 using standard molecular biology techniques.
An identical series of pGL4-Luc2 vectors containing 1, 2,
3, and 4 kb HRH1 promoter fragments encompassing all
of the identified transcription start sites in Human ASM
but not crossing the ExonI/IntronI interface (the most 3'
TSS was at 52,754 bp within AC083855, [33]) were also
generated (Table 1).
Quantification of HRH1 and BDKRB2 core promoter 
transcriptional activity in CHO-K1 or Human ASM
CHO-K1 cells were cultured in complete DMEM (10%
foetal calf serum and 2 mM glutamine) and harvested
using 5 mg/ml trypsin/2 mg/ml EDTA. Cells were plated
at a density of 25,000 cells/well into 48-well tissue culture
plates (Corning, Sunderland, UK) using complete
medium (see above) and allowed to grow for 24 h until
~80% confluent. Complete medium was replaced with
serum free medium and the cells were transfected with
0.12 µg of pGL4-Luc2 using Fugene 6 (Roche) at a 3:1
ratio (Fugene:DNA). For derivatives of pGL4-Luc2 con-
taining the HRH1, BDKRB2 or SV40 control inserts equi-
molar amounts of DNA were used and the amount of
Fugene corrected accordingly. Cells were allowed to grow
for 40 h prior to a PBS wash and harvested using Passive
Lysis Buffer (PLB, 300 µl/well, rocked for 15 min and sub-
jected to freeze/thaw at -80°C). Human ASM experiments
were completed in an analogous manner except cells were
allowed to grow for 24–72 hours until ~80% confluent.
Following transfection cells were allowed to grow for 16
hours prior to the addition of cytokines or drug (at con-
centrations described above). Following 4 or 24 hours,
ASM cells were washed with PBS and harvested using Pas-
sive Lysis Buffer as described in a volume of 100 µl/well.
Firefly luciferase was quantified using 5 µl (CHO-K1) or
20 µl (ASM) of cell lysate and the luciferase assay system
as directed by the manufacturer (Promega) and a Model
TD-20e luminometer (Turner Biosystems, Sunnyvale,
CA). Data was normalised to fold over the empty pGL4-
Luc2 vector. Cytokine or drug treated samples were com-
pared to medium alone treated samples by designated
medium treated samples 100%.
Promoter Database Analysis
Specific transcription factor binding sites were identified
using; BioInformatics & Molecular Analysis Section [34],
Transcription Element Search System [35], TFSEARCH
[36] and WWW Signal Scan [37].
Statistical Analyses
Differences between outcome measures for different treat-
ment groups were compared by Analysis of Variance
(ANOVA) in conjunction with Dunnett's Multiple Com-
parison Post Hoc Test or Students' T test as appropriate.
Figures represent mean values (+/- S.E.M). Statistical anal-
yses were completed using GraphPad Prism (GraphPad,
San Diego, CA), a P value < 0.05 was considered signifi-
cant.
Results
Exposure to Salmeterol, TNFα, IL-13 or IFNγ can augment 
the magnitude of histamine and/or bradykinin stimulated 
inositol phosphate signalling in Human ASM
In order to assess the effect of the micro-environment on
subsequent IPx signalling responses in Human ASM we
incubated cells with a series of pro-inflammatory
cytokines implicated in the pathogenesis of asthma. These
cytokines included; IL-1β, TNFα, IFNγ, or IL-13. The
capacity of the ASM cells to produce IPx in response to
two specific mediators of airway hyper-responsiveness;
histamine and bradykinin and the non-specific Gαq/PLC
activator sodium fluoride was determined. Similarly, the
effect of two drug classes used routinely in the treatment
of asthma was evaluated within the same model; i.e. the
long acting β2-adrenoceptor agonist salmeterol and the
steroid dexamethasone (Table 2). Significant differences
were observed in the capacity of the ASM cells to produce
IPx in response to histamine (p < 0.0001) or bradykinin
(p = 0.0004) following cytokine or drug pre-treatment.
There was not a statistically significant change in the
capacity of the ASM cells to produce IPx following sodium
fluoride stimulation (although differences were observed
and there was a large degree of variation in these data).
More specifically, IL-13, IFNγ and salmeterol were shown
to significantly augment the capacity of the ASM cells to
produce IPx in response to histamine stimulation (p <Respiratory Research 2007, 8:68 http://respiratory-research.com/content/8/1/68
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0.05), however, these effects were modest; IL-13 (144.4 +/
- 9.3%) compared to medium control (100%)), IFNγ
(126.4 +/- 7.5%) and salmeterol (117.7 +/- 5.2%). Simi-
larly, TNFα, IFNγ and salmeterol were shown to augment
bradykinin mediated IPx production in ASM cells (p <
0.05), TNFα (127.4 +/- 8.3%), IFNγ (128.0 +/- 8.4%) and
salmeterol (111.7 +/- 5.0%).
Augmentation of IPx signalling by Salmeterol, TNFα, IL-13 
or IFNγ is accompanied by elevated mRNA levels of the 
relevant GPCR
In order to test the hypothesis that the site of regulation
determining the alteration in IPx signalling observed fol-
lowing cytokine or drug pre-treatment occurs at the recep-
tor locus we determined the mRNA expression levels of
the H1 Histamine and B2 Bradykinin Receptors in our
samples using Real Time PCR, i.e. the two key receptors
mediating histamine or bradykinin activation of human
ASM cells ([29,38], Figure 1). Quantification of the HRH1
mRNA levels identified a significant induction of gene
expression following drug or cytokine treatment for 4 (p <
0.0001) or 24 hours (p < 0.0001) (Figures 1A and 1B). A
significantly elevated level of HRH1 mRNA expression
was observed following 4 hours treatment of Human ASM
with IL-13 (254 +/- 14.5% compared to medium control
(100%)) or IFNγ(228.7 +/- 30.9%). At 24 hours the IL-13
treated cells maintained an elevated level of HRH1 mRNA
expression (298.5 +/- 17.0%) and salmeterol treated cells
demonstrated a significantly elevated level of HRH1
mRNA expression (217.3 +/- 47.1%). Quantification of
BDKRB2 mRNA expression in Human ASM cells follow-
ing cytokine or drug treatment identified a significant
effect on receptor mRNA expression at 4 (p < 0.0001) and
24 hours (p < 0.0001) post treatment (Figures 1C and
1D). A significant induction of BDKRB2 mRNA expres-
sion was observed at 4 hours following TNFα (461.0 +/-
20.4%) or IFNγ (322.1 +/- 53.3%) treatment. Following
24 hours treatment of ASM cells an elevated level of
BDKRB2 mRNA was observed in the TNFα (156.2 +/- 6.5)
and salmeterol (147.1 +/- 14.7%) treated cells. Treatment
of Human ASM cells with IL-13 did not significantly influ-
ence BDKRB2 mRNA expression.
Augmentation of IPx signalling by Salmeterol, TNFα, IL-13 
or IFNγ is not accompanied by elevated mRNA expression 
of the relevant G-protein or phoshopholipase C isoform
To further define the potential mechanisms responsible
for the alterations in the capacity of Human ASM to gen-
erate inositol phosphates we quantified the level of Gαq/
11 and PLCβ1 mRNA expression in these samples. The H1
histamine and B2 bradykinin receptors are thought to sig-
nal via coupling to the Gαq/11 and phospholipase Cβ1
isoforms [39-41]. Analysis of GNA11 and PLCB1 mRNA
expression in Human ASM cells following 4 or 24 hours
treatment with Salmeterol, TNFα, IL-13 or IFNγ did not
identify any significant differences in mRNA levels com-
pared to medium treated cells (data not shown). The
absence of a significant alteration in GNA11 or PLCB1
expression levels does not exclude the potential that these
molecules have altered activation states, which was not
evaluated in the current analyses.
Mapping and bioinformatics analyses of the HRH1 and 
BDKRB2 gene promoters in human ASM predicts multiple 
relevant transcription factor binding sites within the core 
promoter regions
In order to facilitate a more comprehensive analysis of the
potential transcriptional mechanisms involved in HRH1
and BDKRB2 mRNA induction following Salmeterol,
TNFα, IL-13 or IFNγ treatment the BDKRB2 transcription
start site(s) and promoter regions were mapped in
Human ASM cells using 5'RACE (Figure 2). Figure 2A
shows a diagrammatic representation of the identified
5'region and transcript of the BDKRB2 gene in Human
ASM. The BDKRB2 transcript was found to be composed
of three exons separated by 32,109 bp and 3,223 bp
introns respectively spanning ~39 kbps on chromosome
14. The coding region was found to be contained within
Table 2: Effect of pre-treatment with drugs or cytokines on the magnitude of Human ASM IPx signalling responses following 
histamine, bradykinin or sodium fluoride stimulation.
Cytokine/drug Histamine response Bradykinin response NaF response
IL-1β 97.0 (+/- 4.1) 97.8 (+/- 4.3) 85.9 (+/- 8.1)
TNFα 113.0 (+/- 8.4) 127.4 (+/- 8.3) +** 102.8 (+/- 11.9)
IL-13 144.3 (+/- 9.3) +** 113.8 (+/- 7.0) 124.2 (+/- 15.6)
IFNγ 126.4 (+/- 7.5) ** 128.0 (+/- 8.4) +** 132.3 (+/- 14.0)
Salmeterol 117.7 (+/- 5.2) ** 111.7 (+/- 5.0) * 116.2 (+/- 10.9)
Dexamethasone 105.6 (+/- 4.4) 100.3 (+/- 5.0) 113.2 (+/- 10.4)
ASM cells were serum starved for 24 hours and then treated with medium alone, 10 ng/ml IL-1β, 10 ng/ml TNFα, 10 ng/ml IFNγ, 50 ng/ml IL-13, 1 
µM dexamethasone or 1 µM salmeterol for 24 hours. Cells were loaded with [3H]-myo-inositol and IPx production following 100 µM Histamine, 
0.1 µM bradykinin or 10 mM Sodium Fluoride stimulation was determined as described [30]. The IPx production in the medium alone treated cells 
was normalised to 100% and the other treatment groups determined relative to this. Data represents the mean response +/- S.E.M, n = 9 (three 
independent experiments for 3 donors). Data within groups was compared by ANOVA and post hoc Dunnett's Multiple Copmarison Test (+p < 
0.05) or T-Test (*p < 0.05, **p < 0.01).Respiratory Research 2007, 8:68 http://respiratory-research.com/content/8/1/68
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exon 2 and 3 and two close transcription start sites were
identified (Figure 2A and 2B). These data are in excellent
agreement with previous analyses using a placental cDNA
library [42]. The number of sequence clones representing
the two potential transcription starts site are shown, with
the dominant site (TSS1) being 5' to the previously
reported TSS in placental cells ([42], Figure 2A and 2B).
During the course of this study we also characterised the
5' region of the HRH1 gene in Human ASM which has
now been reported elsewhere [33]. The HRH1 transcript
was found to be predominantly (85%) composed of two
exons; a 5' untranslated and an exon containing the cod-
ing region separated by a 104.4 kb intron [33]. The core
HRH1 promoter was identified and three potential tran-
scription start sites were identified [33]. 4 kb of each core
promoter encompassing all of the identified transcription
start sites was used as the basis for the generation of a
series of promoter-reporter constructs. In order to poten-
tially identify transcription factor binding sites with rele-
vance to Salmeterol, TNFα, IL-13 or IFNγ treatment cell
activation (i.e.  NF-κB, AP-1, STAT, CREB and CRE-BP
[43]) within these 4 kb sequences we completed analyses
using transcription factor binding site databases (Figure
2C). Analysis of the HRH1 core promoter sequence using
the TFSEARCH database identified the presence of AP-1 (6
sites, between 1–4 kb), NF-κB (1, 1–2 kb), CRE-BP (3, 1–
4 kb), CREB (1, 3–4 kb), CRE/CRE-BP (1, 3–4 kb) and
STATx (1, 3–4 kb) binding sites (data not shown) how-
ever, only the AP-1 (4 sites, between 1–4 kb) and NF-κB
(1, 1–2 kb) were identified in two or more databases (Fig-
ure 2C). Analysis of the BDKRB2 core promoter using
TFSEARCH identified NF-κB (6 sites, between 0–3 kb),
AP-1 (5, 1–4 kb), STATx (2, 3–4 kb), CREB (3, 0–4 kb),
CREB-BP (4, 0–4 kb) and CREB/CREB-BP (2, 0–4 kb)
binding sites (data not shown). Following analyses using
multiple databases NF-κB (2, 0–1 kb), CREB (2, 0–4 kb)
and AP-1 (9, 0–4 kb) transcription binding sites were
observed in two or more analyses (Figure 2C).
Effect of salmeterol or cytokine treatment on H1 Histamine Receptor and B2 Bradykinin Receptor mRNA expression in  Human ASM Figure 1
Effect of salmeterol or cytokine treatment on H1 Histamine Receptor and B2 Bradykinin Receptor mRNA expression in 
Human ASM. ASM cells were serum starved for 24 hours and then treated with medium alone, 10 ng/ml TNFα, 10 ng/ml IFNγ, 
50 ng/ml IL-13 or 1 µM salmeterol for 4 or 24 hours. mRNA levels of the H1 Histamine Receptor and B2 Bradykinin Receptor 
were quantified using Real Time PCR and normalised using the 18s ribosomal RNA endogenous control. HRH1 mRNA quanti-
fication following 4 hours (A) and 24 hours (B) stimulation. BDKRB2 mRNA quantification following 4 hours (C) and 24 hours 
(D) stimulation. Data is normalised to medium control = 100%, n = 3 independent experiments in triplicate, mean +/- S.E.M. 
Dunnett's Multiple Comparison Test (*p < 0.05).
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Identification of B2 Bradykinin Receptor gene transcription start site(s) and promoter region in Human ASM (A, B) and tran- scription factor analyses of core HRH1 and BDKRB2 promoter (C) Figure 2
Identification of B2 Bradykinin Receptor gene transcription start site(s) and promoter region in Human ASM (A, B) and tran-
scription factor analyses of core HRH1 and BDKRB2 promoter (C). Diagrammatic representation of the BDKRB2 genomic 
structure including identified exons and transcription start sites (TSS) in Human ASM (A) (Exon 1 5'boundary as described 
[42]). Number of pCR-4 clones clustering to the two potential transcription start sites (B). Data represents combined data 
from two Human ASM donors. Relevant transcription factor binding sites identified within the 4 kb of the core promoter of 
HRH1 and BDKRB2 genes by at least two of the four databases utilised (C).
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Promoter-luciferase constructs encompassing 1, 2, 3 and 4 
kb fragments of the HRH1 and BDKRB2 core promoters 
show transcriptional activity in CHO-K1 and Human ASM 
cells
Preliminary luciferase experiments using CHO-K1 cells
transfected with pGL4 constructs for 40 hours provided
clear evidence that all of the HRH1 and BDKRB2 pro-
moter-luciferase plasmids were transcriptionally active
(all >15 fold over pGL4-Luc2 control, p = 0.0002 and p =
0.0004 respectively, data not shown). Interestingly the
greatest activity in CHO-K1 cells was observed for the
plasmids containing the longest segment of the two core
promoters i.e. the HRH1-4 kb (106.5 +/- 34.3 fold over
pGL4-Luc2, p < 0.01) and BDKRB2-4 kb (219.4 +/- 75.3
fold over pGL4-Luc2, p < 0.01) plasmids. Basal activity of
HRH1 promoter containing plasmids transfected into
Human ASM showed low level activity over pGL4-Luc2 at
20 hours post transfection with maximal activity observed
for the pGL4-HRH1-2 kb transfection samples (2.1 +/- 0.2
fold, Figure 3A). Analyses of luciferase activity in Human
ASM cells transfected with the series of BDKRB2 or control
constructs for 20 hours demonstrated significant differ-
ences in activity between constructs (ANOVA, p =
0.0001). The BDKRB2 1 kb (5.6 +/- 0.9 fold) and 4 kb (3.8
+/- 0.8 fold) constructs showed clear activity (Figure 3B).
The pGL4-BDKRB2-3 kb transfection samples showed
similar to pGL4-Luc2 activity (Figure 3B). Transfection of
Human ASM cells with HRH1 promoter containing con-
structs for 40 hours again demonstrated a modest tran-
scriptional activity over pGL4-Luc2 as observed for the 20
hour transfections (maximum HRH1 2 kb, 2.5 +/- 0.8
fold, Figure 3C). Transfection of Human ASM cells with
BDKRB2 promoter constructs again identified the 1 kb
and 4 kb promoter constructs as demonstrating the high-
est level of activity as shown at 20 hours post transfection
(8.7 +/- 1.7 fold and 5.5 +/- 1.1 fold respectively, Figure
3D). pGL4-SV40-Luc2 control luciferase levels were;
CHO-K1 (649 +/- 99 fold) and Human ASM (20 hours
1229 +/- 173 fold, 40 hours 1255 +/- 157 fold). These data
confirmed that the primary ASM cells were being effi-
ciently transfected using this protocol.
Stimulation of HRH1-luciferase transfected Human ASM 
for 4 and 24 hours with IL-13, IFNγ or salmeterol provides 
evidence for multiple mechanisms determining HRH1 
mRNA levels
In order to investigate the effect of cytokines or salmeterol
on HRH1 promoter activity in Human ASM, cells were
transfected with the series of pGL4-HRH1 constructs for
16 hours and then stimulated with the appropriate
cytokine or salmeterol for 4 (Figure 4) or 24 (Figure 5)
hours prior to luciferase quantification. These analyses
were not susceptible to transfection efficiency bias as com-
parisons were made within transfections. Predominantly,
for these pGL4-Luc2 control transfections the background
luciferase activity was not affected by stimulation with
cytokines or salmeterol, however, a significant reduction
in pGL4-Luc2 mediated luciferase activity was observed
following 24 hours TNFα treatment (37.4 +/- 5.0 com-
pared to medium control (100%), Figure 5A). Stimula-
tion of Human ASM cells transfected with pGL4-SV40-
Luc2 control plasmid did not identify any effect of TNFα,
IFNγ, IL-13 or salmeterol treatment for 4 and 24 hours on
SV40 mediated luciferase production (Figures 4B and 5B).
Analyses of Human ASM cells transfected with the HRH1
1, 2, 3 and 4 kb promoter constructs and stimulated for 4
hours with IFNγ, IL-13 or salmeterol provided evidence
that the level of transcription was influenced by treatment
for the 3 and 4 kb constructs (ANOVA, p = 0.05 and p =
0.05 respectively Figures 4E and 4F). However, following
post-hoc analyses only salmeterol significantly aug-
mented transcription of the 4 kb core HRH1 promoter
(224.5 +/- 37.4 versus medium control (100%), p < 0.05
Figure 4F). There was suggestive evidence that IL-13 may
influence transcription of the HRH1 3 kb promoter
(204.1 +/- 50.1) and IFNγ may influence the 4 kb con-
struct (164.4 +/- 36.8, Figures 4E and 4F) although these
differences were not statistically significant. Analyses of
Transcriptional activity of HRH1 and BDKRB2 core promoter  fragments Figure 3
Transcriptional activity of HRH1 and BDKRB2 core promoter 
fragments. Luciferase activity in Human ASM cell lysates 20 
hours post transfection with control, HRH1 and BDKRB2 
luciferase constructs (A and B) (n = 4), Luciferase activity in 
Human ASM cell lysates 40 hours post transfection with con-
trol, HRH1 and BDKRB2 luciferase constructs (C and D) (n 
= 5). Dunnett's Multiple Comparison Test (compared to 
pGL4-Luc2 control **p < 0.01).
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Human ASM cells transfected with the HRH1 1, 2, 3 and
4 kb promoter constructs and stimulated for 24 hours
with IFNγ, IL-13 or salmeterol provided evidence that the
level of transcription was affected for the 1 kb constructs
(ANOVA, p = 0.03, Figure 5C) and that salmeterol signif-
icantly augments the HRH1 1 kb construct transcriptional
activity (250.3 +/- 60.3, p < 0.05, Figure 5C). As previ-
ously, there was evidence that IL-13 influences transcrip-
tion of the HRH1 3 kb promoter (205.3 +/- 90.2, Figure
5E).
Stimulation of BDKRB2-luciferase transfected Human 
ASM for 4 and 24 hours with TNFα and IFNγ does not 
identify a significant effect on BDKRB2 transcription 
however, salmeterol stimulates BDKRB2 transcription
In an analogous manner to that described for the HRH1
promoter analyses the effect of TNFα, IFNγ or salmeterol
on BDKRB2 mediated transcription was evaluated using
the pGL4-BDKRB2-luciferase transfected Human ASM
cells. Following 4 hours stimulation with TNFα or IFNγ
there were no apparent effects on BDKRB2 mediated tran-
scription for the 1, 2, 3 and 4 kb constructs. Salmeterol
treatment resulted in an augmentation of BDKRB2 medi-
ated transcription for the 1, 2, 3 and 4 kb constructs
Effect of salmeterol or cytokine treatment for 24 hours on  HRH1 promoter activity in Human ASM cells transfected  with HRH1-Luciferase or control constructs Figure 5
Effect of salmeterol or cytokine treatment for 24 hours on 
HRH1 promoter activity in Human ASM cells transfected 
with HRH1-Luciferase or control constructs. Human ASM 
cells were transfected and stimulated as described in Figure 
4. Following 24 hours treatment cells were harvested and 
firefly luciferase was quantified. pGL4-Luc2 (A), pGL4-SV40-
Luc2 (B), pGL4-HRH1-1 kb-Luc2 (C), pGL4-HRH1-2 kb-
Luc2 (D), pGL4-HRH1-3 kb-Luc2 (E), pGL4-HRH1-4 kb-Luc2 
(F) transfections. Data is normalised to the mean luciferase 
activity of each construct transfection treated with medium 
alone +/- S.E.M. (n = 5 independent experiments) Dunnett's 
Multiple Copmarison Test (**p < 0.01).
Medium TNFA IFNG IL-13 SALM
0
50
100
150
200
250
300
Treatment
N
o
r
m
a
l
i
s
e
d
R
L
U
(
+
/
-
S
E
M
)
Medium TNFA IFNG IL-13 SALM
0
50
100
150
200
250
300
Treatment
N
o
r
m
a
l
i
s
e
d
R
L
U
(
+
/
-
S
E
M
)
Medium IFNG IL-13 SALM
0
100
200
300
400
Treatment
N
o
r
m
a
l
i
s
e
d
R
L
U
(
+
/
-
S
E
M
)
Medium IFNG IL-13 SALM
0
50
100
150
200
250
300
Treatment
N
o
r
m
a
l
i
s
e
d
R
L
U
(
+
/
-
S
E
M
)
Medium IFNG IL-13 SALM
0
50
100
150
200
250
300
Treatment
N
o
r
m
a
l
i
s
e
d
R
L
U
(
+
/
-
S
E
M
)
Medium IFNG IL-13 SALM
0
50
100
150
200
250
300
Treatment
N
o
r
m
a
l
i
s
e
d
R
L
U
(
+
/
-
S
E
M
)
**
**
B
D
E F
C
A
Effect of salmeterol or cytokine treatment for 4 hours on  HRH1 promoter activity in Human ASM cells transfected  with HRH1-Luciferase or control constructs Figure 4
Effect of salmeterol or cytokine treatment for 4 hours on 
HRH1 promoter activity in Human ASM cells transfected 
with HRH1-Luciferase or control constructs. Complete 
medium was replaced with serum free medium and cells 
were transfected with 0.12 µg of pGL4-Luc2 using Fugene 6 
(Roche) at a 3:1 ratio (Fugene:DNA). For derivatives of 
pGL4-Luc2 containing the HRH1 or SV40 control inserts 
equimolar amounts of DNA were used. Cells were allowed 
to grow for 16 hours prior to the addition of medium alone, 
10 ng/ml TNFα, 10 ng/ml IFNγ, 50 ng/ml IL-13 or 1 µM salm-
eterol. Following 4 hours treatment cells were harvested and 
firefly luciferase was quantified. pGL4-Luc2 (A), pGL4-SV40-
Luc2 (B), pGL4-HRH1-1 kb-Luc2 (C), pGL4-HRH1-2 kb-
Luc2 (D), pGL4-HRH1-3 kb-Luc2 (E), pGL4-HRH1-4 kb-Luc2 
(F) transfections. Data is normalised to the mean luciferase 
activity of each construct transfection treated with medium 
alone +/- S.E.M. (n = 4 independent experiments). Dunnett's 
Multiple Comparison Test (*p < 0.05).
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(409.4 +/- 65.7, 446.7 +/- 111.9, 245.3 +/- 30.8 and 542.4
+/- 148.5 respectively, p < 0.01, Figure 6). Following 24
hours stimulation of BDKRB2-luciferase transfected
Human ASM cells with TNFα, IFNγ or salmeterol a similar
pattern to the 4 hour experiments was observed. TNFα
and IFNγ stimulation did not significantly influence
BDKRB2 mediated transcription (Figure 7). Salmeterol
treatment of BDKRB2-luciferase transfected Human ASM
cells for 24 hours significantly augmented BDKRB2 medi-
ated transcription for the 1, 2 and 4 kb constructs (190.9
+/- 30.0, 208.8 +/- 42.7 and 377.7 +/- 110.7 respectively,
p < 0.05, Figures 7A, 7B, 7D), however, the effect was
apparent for all constructs.
Discussion
In this study we aimed to clarify the effect of pro-inflam-
matory cytokines (IL-1β, TNFα, IFNγ, or IL-13) and two
representatives of drug classes, dexamethasone and salm-
eterol on agonist mediated IPx signalling in Human ASM.
To this end we have demonstrated that TNFα, IFNγ or sal-
meterol can significantly augment bradykinin induced IPx
signalling responses and IL-13, IFNγ or salmeterol can sig-
nificantly augment histamine induced IPx signalling
responses in Human ASM. Further analyses using non-
specific activation of the IPx pathway suggested a regula-
tory mechanism involving the receptor locus, which was
confirmed by the quantification of the H1 Histamine and
B2 Bradykinin receptor mRNA levels in treated cells.
Finally, we sought to identify transcriptional mechanisms
underlying these effects by mapping the core HRH1 and
BDKRB2 promoter regions in Human ASM and complet-
ing promoter-reporter analyses. These data confirmed that
salmeterol can induce HRH1 and BDKRB2 transcription,
however, the cytokine analyses suggested a role for addi-
tional mechanisms regulating cytokine induced GPCR
mRNA levels.
The mechanisms underlying the potentially deleterious
effects of prolonged use of β2-adrenoceptor agonists in
asthma are unclear at this time. This study represents the
first demonstration that salmeterol can modestly augment
bradykinin induced IPx signalling in Human ASM and has
identified a mechanism involving the induction of B2
Bradykinin receptor mRNA via increased transcription at
Effect of salmeterol or cytokine treatment for 24 hours on  BDKRB2 promoter activity in Human ASM cells transfected  with BDKRB2-Luciferase constructs Figure 7
Effect of salmeterol or cytokine treatment for 24 hours on 
BDKRB2 promoter activity in Human ASM cells transfected 
with BDKRB2-Luciferase constructs. Human ASM cells were 
transfected and stimulated as described in Figure 4. Following 
24 hours treatment cells were harvested and firefly luciferase 
was quantified. pGL4-BDKRB2-1kb-Luc2 (A), pGL4-
BDKRB2-2kb-Luc2 (B), pGL4-BDKRB2-3kb-Luc2 (C), pGL4-
BDKRB2-4kb-Luc2 (D) transfections. Data is normalised to 
the mean luciferase activity of each construct transfection 
treated with medium alone +/- S.E.M. (n = 5 independent 
experiments). Dunnett's Multiple Comparison Test (*p < 
0.05, **p < 0.01).
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Effect of salmeterol or cytokine treatment for 4 hours on  BDKRB2 promoter activity in Human ASM cells transfected  with BDKRB2-Luciferase constructs Figure 6
Effect of salmeterol or cytokine treatment for 4 hours on 
BDKRB2 promoter activity in Human ASM cells transfected 
with BDKRB2-Luciferase constructs. Human ASM cells were 
transfected and stimulated as described in Figure 4 except 
derivatives of pGL4-Luc2 containing the BDKRB2 inserts 
were used. Following 4 hours treatment cells were harvested 
and firefly luciferase was quantified. pGL4-BDKRB2-1kb-Luc2 
(A), pGL4-BDKRB2-2kb-Luc2 (B), pGL4-BDKRB2-3kb-Luc2 
(C), pGL4-BDKRB2-4kb-Luc2 (D) transfections. Data is nor-
malised to the mean luciferase activity of each construct 
transfection treated with medium alone +/- S.E.M. (n = 4 
independent experiments). Dunnett's Multiple Copmarison 
Test (**p < 0.01).
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the core promoter. The promoter-reporter analyses
showed a robust and pronounced effect of salmeterol on
BDKRB2 promoter driven transcription which correlated
with the identification of a consensus CREB site at -121 in
the BDKRB2 promoter suggesting that all constructs (1–4
kb) should show induction of transcription. Interestingly,
it has recently been shown that a CREB binding site at -44
to -51 in the rat BDKRB2 promoter is a major determinant
of transcriptional regulation of the rat gene [44]. Salme-
terol was also shown to augment histamine induced IPx
signalling in Human ASM via an identical mechanism
involving the H1 Histamine receptor, however, the
reporter driven transcriptional affects were more modest
potentially reflecting the low level of HRH1 promoter
activity observed in the current study. These data extend
our recent study that demonstrated that the short acting β2
adrenoceptor agonists; salbutamol and isoprenaline
could augment histamine induced IPx signalling
responses [24] and show that multiple contractile agent
responses are affected by prolonged use of this class of
drugs. In support of the current findings, previous data
examining the effect of β2 adrenoceptor agonists on hista-
mine mediated contraction in bovine ASM demonstrated
a modest augmentation (1.5 fold) following fenoterol
pre-treatment (18 hours) which was shown to be accom-
panied by an increase in HRH1 mRNA expression [28]. In
this bovine system both transcriptional and post-tran-
scriptional regulation were identified as determinants of
HRH1 mRNA expression [28]. The clinical implications of
these findings are that this mechanism may at least in part
explain the accumulating evidence to suggest that pro-
longed use of long acting β2 adrenoceptor agonist mono-
therapy can lead to adverse effects in asthma as
demonstrated in the SMART study [22]. This study of sal-
meterol use for 28 weeks was a multicentre, randomized,
double blind, parallel group, placebo controlled design
involving 26,355 subjects at 6,163 sites in the United
States [22]. Interim analyses demonstrated that there was
a significant increase in respiratory related deaths (24 vs.
11, RR 2.16 (95% CI 1.06 to 4.41)) and asthma related
deaths (13 vs. 3, RR 4.37 (95% CI 1.25 to 15.34)) in the
salmeterol versus placebo group [22].
Several studies have identified a direct interaction
between cytokines and Human ASM leading to alterations
in the capacity of airway smooth muscle in culture to
respond to contractile agents [9,10]. TNFα can augment
bradykinin induced Ca2+ signalling (~2 fold) and IPx sig-
nalling (~2 fold) [12]. We have demonstrated similar
affects and identified that induction of BDKRB2 mRNA is
a feature of this response. Our data suggested that this
induction of BDKRB2 mRNA may involve other mecha-
nisms than transcription at the core promoter e.g. post-
transcriptional mechanisms including RNA stability. The
critical importance of 3'UTRs of genes determining mRNA
expression has been established including a role for AU-
rich elements (ARE) and RNA stabilising regions [45].
Several RNA binding proteins including; tristetraprolin
(TTP), human antigen R (HuR) and AU-rich factor 1
(AUF1) have been identified that mediate RNA stability
and therefore determine mRNA levels [46]. Interestingly,
TNFα has been shown to induce HuR activity leading to
increased eotaxin mRNA stability [47]. In support of the
current study, TNFα has been shown to augment BDKRB2
mRNA expression in human embryonic lung fibroblast
cells [48]. Nuclear run on assays suggested a prominent
role for post-transcriptional mechanisms leading to ele-
vated BDKRB2 mRNA following TNFα treatment [48]
which would at least in part explain the lack of transcrip-
tional regulation identified in the current promoter-
reporter analyses. The 3'untranslated region of the
Human B2 bradykinin receptor has been identified a key
determinant of BDKRB2 mRNA expression [49]. TNFα
has also been shown to augment bradykinin induced con-
tractile responses in a mouse tracheal ring model and a
Schematic representation of mechanisms involved in the  induction of hyperresponsiveness in Human ASM Figure 8
Schematic representation of mechanisms involved in the 
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GPCR leading to increased IP3 production in response to 
specific contractile agents (as demonstrated in the current 
manuscript). In addition, cytokines can up-regulate CD38 
leading to subsequent increased cADPR production [9]. Sec-
ond messengers IP3 and cADPR activate the Ryanodine and 
IP3 receptor respectively leading to elevated calcium release 
from intracellular stores and downstream contractile 
responses.
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role for increased B2 bradykinin receptor mRNA was iden-
tified [50] suggesting the mechanism exists across species.
IL-13 has been shown to augment histamine and bradyki-
nin induced Ca2+ signalling (~30% and 40% respectively)
in Human ASM [13]. In the current study we have shown
IL-13 specifically augments histamine induced IPx signal-
ling and that this specificity involved selective regulation
at the receptor locus. The modest induction of HRH1 tran-
scription mediated by IL-13 in the promoter-reporter
analyses again suggests multiple mechanisms determine
the HRH1 mRNA level, i.e. a transcriptional mechanism
does not adequately explain the robust >3 fold induction
in mRNA levels observed. As part of a wider microarray
study IL-13 has previously been shown to induce HRH1
expression in Human ASM (~2.6 fold, 4 hours) [51].
Interestingly, IL-4 has been shown to induce activity of the
RNA stablilising protein HuR and increase mRNA expres-
sion levels of eotaxin in epithelial cells [47]. IL-4 and IL-
13 can both activate the STAT6 pathway and therefore
potentially the IL-13 dependent increase in HRH1 mRNA
may involve post-transcriptional mechanisms involving
HuR.
IFNγ has been shown to augment bradykinin induced
Ca2+ signalling (~1.5 fold) in Human ASM [52]. We have
demonstrated that IFNγ can augment both histamine and
bradykinin induced IPx signalling via induction of GPCR
mRNA levels. Analysis of the BDKRB2 and HRH1 core
promoter did not identify a transcriptional mechanism to
explain the induction of mRNA levels in treated cells.
Importantly, the β1-adrenergic receptor, a member of the
GPCR family has been shown to be regulated via posttran-
scriptional mechanism which determine mRNA stability
and level [53]. By inference, our core promoter analyses
potentially suggest that post-transcriptional mechanisms
may be important for GPCR mRNA regulation by
cytokines.
In agreement with the proposed mechanism described in
the current study, IFNγ has been shown to induce cystei-
nyl leukotriene receptor 1 (CysLTR1) mRNA expression in
Human ASM with subsequent augmentation of LTD4
mediated Ca2+ signalling responses [26]. These data sug-
gest that regulation of Human ASM responses to multiple
contractile agents involves regulation at the GPCR locus.
In the current study we did not identify any effect of dex-
amethasone or IL1β on Human ASM IPx signalling in
contrast to others [15,38], which may reflect cell donor/
experimental differences. Previous data has demonstrated
that e.g. IL-13 can augment KCl induced force generation
in mouse tracheal rings suggesting a regulatory mecha-
nism downstream of that examined in the current study
[13]. A mechanism to explain these observations has been
identified involving cytokine activation leading to ele-
vated CD38 and subsequent cyclic ADP ribose (cADPr)
which activates the ryanodine receptor (RyR) and modu-
lates the calcium response in Human ASM [9]. Therefore,
it is likely that regulation at the GPCR locus demonstrated
in the current study provides some specificity and ampli-
fication of Ca2+ responses via IP3 generation and that
induction of CD38 also contributes to the overall magni-
tude of Ca2+ and contractile responses (see Figure 8). Our
finding that IL-13 did not influence bradykinin induced
IPx production or BDKRB2 mRNA levels may suggest that
augmentation of this specific agonist response is more
dependent on the CD38/cADPr pathway although we can
not exclude the influence of different cell donors/experi-
mental designs.
These data demonstrate that a range of pro-inflammatory
cytokines known to be over-expressed in the asthmatic
lung alter Human ASM IPx signalling capacity and by
inference may be involved in the molecular basis of AHR
in asthma. It is important to note that TNFα identified in
the current analyses as augmenting IPx production has
also been shown to augment adenylyl cyclase activity in
Human ASM [27]. Therefore, the potential contractile
effects resulting from increased IPx production in
response to cytokine and spasmogen may at least in part
be countered by the increased relaxation capacity of ASM
due to an augmentation of cyclic AMP production. It is
interesting that IFNγ augmented responses to multiple
contractile agents suggesting that this cytokine could have
a key role in AHR development during e.g. viral infection
and in asthma per se as CD8+IFNγ + cell numbers in the
airways of asthma subjects correlate with AHR [8]. The
finding that salmeterol can modestly augment Human
ASM responses to contractile agents and potentially lead
to AHR also has clinical implications. This study has iden-
tified some interesting findings however, the use of single
dose and time points may have identified sub-optimal
effects. Similarly, other limitations include the measure-
ment of global IPx production as an outcome measure
and not specific IPx production, cytosolic calcium and
contractile responses which would have been desirable.
Conclusion
We have presented evidence that the regulation of Human
ASM responses to contractile agents can at least in part be
explained by regulation at the GPCR locus. Several
cytokines (TNFα, IFNγ, IL-13) and salmeterol modestly
augment histamine and bradykinin IPx signalling
responses in cultured Human ASM cells in a cytokine and
agonist specific manner. This augmentation was accom-
panied by elevated mRNA levels of the specific GPCR pro-
viding a mechanism to explain this specificity. Finally, we
demonstrated that cytokine modulation of HRH1 and
BDKRB2 mRNA levels may involve additional mecha-
nisms to a transcriptional mechanism involving the coreRespiratory Research 2007, 8:68 http://respiratory-research.com/content/8/1/68
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HRH1 and BDKRB2 promoters. The effects observed for
salmeterol mediated GPCR mRNA induction did involve
transcriptional regulation at the core promoter. While the
effects on IPx signalling were modest there is accumulat-
ing evidence that small changes in IPx signalling and sub-
sequent cytosolic calcium concentrations can have
physiological implications for contractile responses and
airway hyper-responsiveness. These findings provide a
greater insight into the molecular basis of AHR in asthma.
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